Elinzanetant’s impact on vasomotor symptoms prompts study on menopausal sleep disturbances

Following positive topline data for moderate to severe vasomotor symptom treatment, a phase 2 study of elinzanetant is underway to assess its safety and efficacy on sleep disturbances associated with menopause, Bayer said in a news release.
Elinzanetant (Bayer) is an investigational dual neurokinin-1, 3 receptor antagonist. In the OASIS 1 and 2 phase 3 studies, elinzanetant demonstrated statistically significant reductions in both the frequency and severity of moderate to severe vasomotor symptoms related to menopause. Elinzanetant was also associated with reduced hot flash frequency from

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart